Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Pharma Holdings Reports Improved 2008

publication date: Mar 18, 2009

China Pharma Holdings said its 2008 revenues climbed 54% to $51 million. Net income (excluding foreign exchange) rose 39% to $17.8 million, producing a net margin of 35%. Net income would have been even better, but the company’s tax rate rose from zero in 2007 to 9% in 2008. Unfortunately, increasing accounts receivable numbers have been the price for expanding its top line so quickly. The company said it ended 2008 with $15.9 million in accounts receivable, a sizeable increase from $5.4 million a year earlier. More details...

Stock Symbol: (OTCBB: CPHI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital